Ispecimen Inc. · NASDAQ:ISPC
Ispecimen — Investor Presentation (November 2022)
29 slides from Ispecimen's investor presentation, Nov 8, 2022
Slide 1: An online marketplace for human biospecimens
CONNECT. INNOVATE. TRANSFORMING PROCUREMENT BIOSPECIMEN An online marketplace for human biospecimens November 2022 Investor Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditio
Slide 3: Investor Highlights
Investor Highlights >200 Healthcare Provider / Supplier Organizations 1. Early-stage opportunity with a first mover advantage 2. Unique two-sided marketplace disrupting the biospecimen procurement process 3. Strong revenue growth with a 6-year CAGR 59% of 4. Growing data differentiator asset that’s
Slide 4: Our Vision
Our Vision Accelerate scientific discovery via an online marketplace that empowers researchers to instantly search for and gain access to patients, biospecimens, and data across a global network healthcare providers of 4
Slide 5: Human Biospecimens are Essential for Life Science R&D
Human Biospecimens SUPPLY HEALTHCARE PROVIDERS are Essential for Life Science R&D DEMAND LIFE SCIENCE RESEARCHERS Patients Biospecimens Data Organizations Applications Biofluids Plasma, Serum, Urine, Saliva Industry Medical Record Solid Tissue Lung, Breast, Colon, Brain Academia Stem & Immune Cells
Slide 6: Large and Inefficient Biospecimen Market
Large and Inefficient Biospecimen Market $3 - $4 Billion Worldwide yearly spend on human biospecimen procurement 1 Disconnected Market Participants in Need of a Marketplace Solution 10 - 15% Annual Growth Fueled by precision and regenerative medicine research 2 With an Inefficient Supply Chain Manua
Slide 7: Market Inefficiencies
Market Inefficiencies Difficulties Connecting, Searching, and Compliantly Transacting 6-12 months on average to develop relationships, requiring the involvement of many stakeholders 3 PATIENTS PROVIDERS RESEARCHERS IT / Informaticist Informaticist Principal Investigator & Specimen Operations Researc
Slide 8: Inefficiencies Lead to Losses
Inefficiencies Lead to Losses Providers miss revenue and research opportunities Researchers limit their work > 1 Billion Patient encounters yearly in the U.S. where a specimen could be provided for research 4 10 years ago, 81% of researchers said they limit the scope of their work due to difficultie
Slide 9: The iSpecimen Marketplace Solution
The iSpecimen Marketplace® Solution An Online Platform That Instantly Connects Researchers to a Global Network of Patients, Biospecimens, and Data to Accelerate Time to Discovery Saves months in the average biospecimen procurement process PATIENTS PROVIDERS RESEARCHERS IT / Informaticist Scientist &
Slide 10: Full-Service Procurement
Full-Service Procurement CONTRACTING COMPLIANCE MANAGEMENT We Not Only Connect Suppliers and Customers, but Also Manage the Entire Procurement Process STUDY DESIGN & SPECIFICATION SPECIMEN SEARCH & SELECTION STUDY/ORDER MANAGEMENT COLLECTION KIT BUILDING SUPPLIER SITE TRAINING SPECIMEN LOGISTICS SPE
Slide 11: Suppliers and Researchers Benefit
Suppliers and Researchers Benefit Providers… Increase Revenue Instantly connect to a global network of researchers Researchers… Save Money Instantly connect to a global network of specimen providers Advance Discovery Support research mission and advance diagnostic, therapeutic, and vaccine research
Slide 12: Growing Supplier Adoption
Growing Supplier Adoption Cumulative Supplier Organizations Under Agreement 2015 September 30, 2022 217 Unique Supplier Organizations Provide Access to: >150 Clinical Research Centers 1000+ Hospitals 200 181 >60 Clinical and Pathology Labs 000’s Clinics and Practice Groups 54% CAGR Number of Supplie
Slide 13: Growing Researcher Adoption
Growing Researcher Adoption Cumulative Customer Organizations with Purchases 2015 – September 30, 2022 Annual Revenue ($000) - Unaudited 2015-18, 2022 2015 – September 30, 2022 $11,135 59% CAGR Customers (2015 – Sept. 30, 2022) 59% CAGR Revenue (2015 – 2021) 135 $700 2015 2016 2017 2018 2019 2020 20
Slide 14: Growing Marketplace Adoption
Growing Marketplace Adoption Cumulative Researcher and Supplier Marketplace Users 2015 – September 30, 2022 Annual Researcher and Supplier Marketplace Logins* 2015 – September 30, 2022 6,445 27,221 5,218 92% CAGR Registered Users 50% CAGR Marketplace Logins (2015 – 2021) (2015 – Sept. 30, 2022) 9,51
Slide 15: Growing Data Asset
Growing Data Asset Clinical Specimen Records 80M+ Banked Specimen Records 1.2M+ Millions of Unique Specimen and Patient Records provide a competitive advantage and differentiator now and available for future adjace nt opportunities such as patient search, clinical trial recruitment, and data licensi
Slide 16: Statements of Operations (Unaudited)
Statements of Operations (Unaudited) iSpecimen Inc. Condensed Statements of Operations (Unaudited) Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Revenue $ 2,583,412 $ 2,718,534 $ 7,440,760 $ 8,586,217 Non-COVID-19 Revenue (Q3 2021 vs. Q3 2022) Cost of revenue 1
Slide 17: Balance Sheets
Balance Sheets iSpecimen Inc. Condensed Balance Sheets September 30, 2022 December 31, 2021 (Unaudited) Cash $ 20,657,719 $ 27,738,979 Accounts receivable, net of allowance 1,784,805 3,002,442 Tax credit receivable, net of current portion 140,873 140,873 Internally developed software, net 3,434,344
Slide 18: Fully Diluted Shares of Common Stock Outstanding
Fully Diluted Shares of Common Stock Outstanding Diluted Shares of Common Stock Shares issuable upon vesting of restricted stock units 346,617 Shares issuable upon exercise of stock options 166,248 Shares issuable upon exercise of warrant to purchase common stock 1,415,000 18 Total diluted shares at
Slide 19: Management Team
Management Team 19 Tracy Curley | Interim Chief Executive Officer, Chief Financial Officer and Treasurer Ms. Curley brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging companies like iSpecimen and joined iSpecimen in August 20
Slide 20: Investor Summary
Investor Summary >200 Healthcare Provider / Supplier Organizations 1. $3B-$4B global biospecimen market growing at 10-15% per year 2. Early-stage opportunity with a first mover advantage 3. Unique two-sided marketplace disrupting the biospecimen procurement process 4. Strong revenue growth with a 6-
Slide 21: Contact Us
CONTACT US iSpecimen Inc. 450 Bedford Street Lexington, MA 02420 CONNECT. INNOVATE. investors@ispecimen.com ispecimen.com Sign up for free iSpecimen Marketplace account at www.ispecimen.com
Slide 22: Appendix
Appendix @iSPECIMEN’ 22
Slide 23: Strategic Evolution
Strategic Evolution START UP Company Ideation and Self-Funding PHASE 1 Proof of Concept PHASE 2 Critical Mass of Suppliers and Early Customer Adoption PHASE 3 Expansion via the Online iSpecimen Marketplace™ 23 2010 – 2011 2012 – 2013 2014 – 2017 2018 – June 30, 2022 0 Customers 1 Supplier Agreement
Slide 24: iSpecimen Marketplace UI/UX
iSpecimen Marketplace UI/UX iSpecimen Marketplace™ Search Millions of Specimens Across Our Network Hematopoietic & Immune Cells Request hematologic products prospect vely collected from donors Research Specimens Search our onlineinventory of research specimens ready lor procurement Clinical Specimen
Slide 25: iSpecimen Marketplace UI/UX
iSpecimen Marketplace UI/UX ====== ---------------------=0 Exact Match (AND) Specimen Format Select Specimen Format... - II a ViewQuote 12744 Cases Search Facets Reset fi lters Sort Relevance c'J PATIENT Pnrr. Olse Co Pat Det - Breast Breast Cancer 2007 - USA (Research Use) 71yrs - Female - Caucasia
Slide 26: Marketplace UI/UX
Marketplace UI/UX iSpecimen breast Exact Match (AND) [ Sex: Female x J [ Specimen Age: 0 to 20 x J Age at Collection: o to 90 x Country of Collection: USA x Specimen Format Plasma-DTA Matched Specimen Select Matched Speci mens... - II 1342 Ca ses Search Facets Reset filters SortRelevance c!J PATIENT
Slide 27: iSpecimen Marketplace UI/UX Track and Manage Requests
iSpecimen Marketplace UI/UX 27 Track and Manage Requests Request a Quote View Quote Request and Add More Specimens
Slide 28: Sources Cited
Sources Cited Page Note Source Cited 7 1 iSpecimen estimates based on In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Immunochemistry, Molecular Diagnostics) By End-use, By Region, And Segment Forecasts, 2021 – 2027. Grandview Research, Jan
Slide 29: iSpecimen Marketplace
@ iSPECIMEN Marketplace’